• MJHLS Brand Logo

© 2026 MJH Life Sciences™ and The Center for Biosimilars - Biosimilars, Health Economics & Insights. All rights reserved.

All News

    Top 5 Most-Read Biosimilar News of 2025

    December 31st 2025

    By Skylar Jeremias

    Article

    Explore the latest developments in the US biosimilar market, highlighting key approvals, challenges, and future trends shaping patient access in 2025.

    Top 5 Most-Read Gastroenterology Articles of 2025

    December 29th 2025

    By Skylar Jeremias

    Article

    Explore this year's advancements in gastroenterology biosimilars, highlighting key FDA approvals and market dynamics impacting IBD treatment options.

    Top 5 Most-Read Ophthalmology Articles of 2025

    December 26th 2025

    By Skylar Jeremias

    Article

    The most-read ophthalmology biosimilar stories of 2025 included FDA approvals and real-world data.

    Top 5 Most-Read Bone Health Articles of 2025

    December 24th 2025

    By Skylar Jeremias

    Article

    Explore the latest advancements in denosumab biosimilars, enhancing treatment options for osteoporosis and bone metastases in 2025.

    BioRationality: Entering a New Era of Affordable Biosimilar Development

    December 23rd 2025

    By Sarfaraz K. Niazi, PhD

    Article

    Biosimilar development costs could plummet from $100 million to $5 million, enabling smaller companies to enter the market and revolutionize access to essential medicines.

    Top 5 Most-Read Policy Articles of 2025

    December 22nd 2025

    By Skylar Jeremias

    Article

    In 2025, the latest biosimilar policy developments included bipartisan efforts to enhance affordability and reduce barriers in the pharmaceutical landscape.

    Top 5 Most-Read Regulatory Articles of 2025

    December 19th 2025

    By Skylar Jeremias

    Article

    Discover the top 5 regulatory biosimilar news of 2025, highlighting FDA approvals that enhance treatment options and competition in health care.

    First Natalizumab Biosimilar Tyruko Launches, Expanding Access in Multiple Sclerosis

    December 18th 2025

    By Skylar Jeremias

    Article

    Tyruko, the first natalizumab biosimilar for multiple sclerosis, promises significant savings and competition in the US market.

    Denosumab, Golimumab Biosimilars Clear Major Regulatory Milestones in Europe, as US Hurdles Remain

    December 16th 2025

    By Skylar Jeremias

    Article

    Biosimilar developers achieve key European approvals for denosumab and golimumab, enhancing patient access while facing US market entry delays.

    BioRationality: FDA Issues New Guidance on Promotional Communications for Biosimilar Products

    December 11th 2025

    By Sarfaraz K. Niazi, PhD

    Article

    FDA's new guidance clarifies promotional practices for biosimilars, ensuring accurate marketing and preventing misleading claims in the competitive landscape.